Extended-release buprenorphine outcomes among treatment resistant veterans.

Buprenorphine Extended-Release (BUP-XR) is an FDA approved, monthly subcutaneous injection for opioid use disorder. This formulation provides an alternative for patients who have difficulty adhering to daily sublingual buprenorphine; however, its cost may be prohibitive compared to other medication alternatives. The objective of this project was to evaluate the effectiveness of BUP-XR and provide a rationale for its utilization in health care facilitates.